Replies to post #8343 on NorthWest Biotherapeutics Inc (NWBO)

[Astavakra]

Yes, a few, FWIW. In the absence of news, a speculative (without revenue) stock will drift lower, like entropy. Combine that with the hex put on the entire sector, uncertainty about what the delay in the efficacy decision is all about, and AF's relentless antics and I think you have the answer.
Consolation is that when good news comes, and as ASCO draws nearer, pps should jump -- barring any sucker punches from out of nowhere. IMO.

[staccani]

Market makers/HF's (or market manipulators I should say), slowly and relentlessy drive the price lower and lower on small volumes (usually with computerized HFT) sometimes even selling shares each other, in order to get weak hands retail investors (who get scared or bored) shares on the cheap. Strange as it may see, this is a very good sign, as it measn that they want retail out of the stock. Also expect multiple bear raids (short sudden dramatic price drops) before ASCO. They use them to take out stop losses, so never put stop losses as these crooks will steal you shares. Best thing to do is just buying on the dips and wait for ASCO and Phase III results.

[longtermthinker]

Why is the price going south?
Are you kidding me? Happy Halloween! Follow the PR trail.
The CEO has investors scared sh!tless.
She looks incompetent, desperate or just plain dishonest,
take your pick. This whole back and forth with AF
is a disaster for investor confidence and the stock price.
Failure to address direct criticisms made by AF are
obvious to smart investors. If you are going to respond to
somebody like that, you better make it good and to the point.
Then too...is the fact that we have an "expanded" trial,
right in the middle of the ongoing review...a review, you
may remember, that many true believers would result in a "halt"
based on the existing data. So we have a play-on opinion
based on safety, no word on efficacy, and an expanded trial
whose endpoints are in question and for which the review process
appears to be back to step 1. I am short on this, and really
glad too. Made good money on this one when things looked
promising. It is now a long shot in my book, with some form
of approval likely, but with "blockbuster" designation
completely out of bounds.